The BCORL1 Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function analysis of the BCORL1 gene in a human colorectal adenocarcinoma background. This product provides a genetically heterogeneous pool of HT29 cells harboring targeted disruption of BCORL1, enabling researchers to investigate the functional consequences of BCORL1 ablation without clonal selection bias. The polyclonal format preserves population-level heterogeneity, making it suitable for pooled functional screens, dose?Cresponse assays, and high-content phenotyping where clonal artifacts must be minimized. As a ready-to-use knockout model, these cells streamline downstream workflows including transcriptomic profiling, drug sensitivity testing, and migration assays.
HT29 cells are an epithelial, adherent cell line derived from a human colorectal adenocarcinoma and serve as a widely accepted model for intestinal epithelial biology and colorectal cancer research. This cell line exhibits typical epithelial morphology and expresses key markers of intestinal differentiation, such as mucins and tight junction proteins. HT29 cells have been extensively characterized in studies of colon cancer pathogenesis, barrier function, and tumor microenvironment interactions. Their robust growth characteristics and compatibility with standard 2D and 3D culture systems, including spheroid and organoid formats, make them an ideal host for CRISPR-engineered knockout models. The employment of HT29 cells as the genetic background for BCORL1 disruption thus permits direct interrogation of the gene??s role within a well-defined colorectal cancer context.
BCORL1 encodes a transcriptional corepressor that assembles into multiprotein complexes with class II histone deacetylases (HDAC4, HDAC5, HDAC7), CtBP, and the BCL6 proto-oncoprotein to mediate gene silencing via histone deacetylation. This complex is recruited to chromatin through direct DNA-binding factors such as BCL6, which recognizes specific promoter elements in target genes including CDKN1A, MYC, and AP-1-regulated loci. By removing acetyl groups from lysine residues on histone tails, BCORL1-containing complexes condense local chromatin structure and actively repress transcription of cell cycle regulators and differentiation factors. In hematopoietic lineages, BCORL1 is known to function as a tumor suppressor, with recurrent loss-of-function mutations observed in myelodysplastic syndromes and acute myeloid leukemia. The regulatory inputs governing BCORL1 expression remain poorly defined, though promoter methylation and transcriptional modulation are suspected mechanisms.
Introducing BCORL1 disruption into HT29 colorectal cancer cells addresses a critical gap in understanding how this corepressor operates outside the hematopoietic compartment. While BCORL1 is implicated in blood malignancies, its contribution to solid tumor biology is less characterized. In colorectal cancer, where aberrant transcriptional repression and epigenetic dysregulation are hallmarks of disease progression, BCORL1 knockout can reveal previously hidden tumor-suppressive or oncogenic activities. Predicted consequences include derepression of target genes such as CDKN1A and MYC, leading to altered proliferation kinetics, enhanced apoptosis sensitivity, or modified migratory behavior. This model therefore enables systematic evaluation of BCORL1-dependent transcriptional networks in an epithelial cancer milieu, potentially uncovering synthetic lethal relationships or epigenetic vulnerabilities exploitable by HDAC inhibitors or other chromatin-modifying drugs.
The BCORL1 Knockout HT29 Polyclonal Cells are appropriate for a range of investigative applications, including functional genomics, epigenetic drug screening, and mechanistic studies of transcriptional corepressor biology. Researchers can measure gene expression changes via RNA-seq or RT-qPCR, quantify protein-level effects using western blotting, and assess cellular phenotypes through colony formation, transwell migration, and apoptosis assays. Additionally, reporter gene assays can dissect BCORL1-mediated silencing of specific promoter constructs. This knockout model also serves as a controlled background for testing candidate therapeutic agents that target HDACs or corepressor interactions. For further information or to discuss customization options, please contact Ascent Research.
